<DOC>
	<DOCNO>NCT02478281</DOCNO>
	<brief_summary>A Phase 1 trial ass single-dose safety , tolerability , pharmacokinetic ( PK ) Methylene Blue Injection , USP 1 mg/kg healthy adult voluneetrs .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetic Study Methylene Blue Following 1 mg/kg Intravenous Dose Healthy Adults</brief_title>
	<detailed_description>This open-label , single-center , one-arm , safety , tolerability , PK study healthy male female volunteer Methylene Blue Injection , USP . Following overnight fast , twelve healthy adult male female volunteer receive single dose study drug dose 1 mg/kg solution per kg give intravenously period 5 minute follow serial venous blood sample 0.042 , 0.083 , 0.167 , 0.25 , 0.5 , 0.75 , 1 , 2 , 3 , 4 , 6 , 8 , 10 , 16 , 36 , 48 , 72 hour postdose .</detailed_description>
	<mesh_term>Methemoglobinemia</mesh_term>
	<mesh_term>Methylene Blue</mesh_term>
	<criteria>Healthy adult male female volunteer , 1860 year age , inclusive . Weigh least 52 kg male 45 kg female within normal range accord accept normal value Body Mass Index ( BMI ) chart 18.529.9 kg/m² inclusive . Medically healthy clinically significant laboratory profile , vital sign , ECG 's ; deem PI . For female childbearing potential : either sexually inactive ( abstinent ) 14 day prior first dose throughout study use acceptable birth control method . Female subject claim sexually inactive , become sexually active course study must agree use barrier method ( e.g . condom , diaphragm ) spermicide time start sexual activity least 30 day follow dosing . In addition , female subject childbearing potential advise remain sexually inactive keep birth control method least 30 day follow dosing . Females nonchildbearing potential must undergo one follow sterilization procedure least 6 month prior Day 1 : Hysteroscopic tubal ligation ( copy confirmation test ) use barrier method ( condom diaphragm ) spermicide throughout study ; Bilateral tubal ligation use barrier method ( condom diaphragm ) spermicide throughout study ; Hysterectomy ; Bilateral oophorectomy postmenopausal amenorrhea least 1 year prior Day 1 follicle stimulate hormone ( FSH ) serum level ≥ 40 mIU/mL . Females hormone replacement therapy may deem eligible participation study even FSH level &lt; 40 mIU/mL , able provide documentation FSH level 40 mIU/mL initiation hormone replacement therapy . Males must use condom spermicide engage sexual activity must agree refrain sperm donation checkin 90 day postdose . Willing answer inclusion exclusion criterion questionnaire checkin . Give voluntary write informed consent participate study . Be able comply protocol assessment therein . History presence significant cardiovascular , pulmonary , hepatic , renal , hematological , gastrointestinal , endocrine , immunologic , dermatologic , neurological , psychiatric disease opinion PI . History presence alcoholism within past 2 year . History presence drug abuse within past 2 year . History presence hypersensitivity idiosyncratic reaction Methylene Blue . History presence G6PD dehydrogenase deficiency , retinopathy , blood disorder , myasthenia gravis , psoriasis , epilepsy , clinically significant allergy ( except mild form hay fever ) , clinically significant medical condition , opinion PI , might interfere study participation . History laboratory evidence renal insufficiency . Any screening laboratory test clinically significant abnormality opinion PI ( include cell blood count , creatinine , liver function test ) . Have use drug act seotonin reuptake inhibitor ( SRIs ) e.g . selective serotonin reuptake inhibitor ( SSRIs ) , tricyclic antidepressant ( TCAs ) , norepinephrinedopamine reuptake inhibitor ( NDRIs ) , triptans , ergot alkaloid within 30 day ( 5 halflives compound , whichever long ) prior study drug dosing . Female subject pregnant lactating , female subject likely become pregnant study . Had positive result urine drug/alcohol screen screen checkin . Had positive result screen HIV , HBsAg , HCV . Seated blood pressure le 90/40 mmHg great 140/90 mmHg screening . Heart rate lower 40 bpm high 99 bpm screening . QTc interval &gt; 430 msec ( male ) &gt; 450 msec ( female ) deem clinically abnormal PI use drug agent suspect cause QT prolongation torsade de pointes within 14 day ( 5 half life compound , whichever long ) prior study drug dosing . Have special diet ( whatever reason ) within 28 day prior study drug dosing , throughout study . Have make donation blood significant blood loss within 56 day prior study drug dosing . Have make plasma donation within 7 day prior study drug dosing . Have receive Methylene Blue within 72 hour prior study drug dosing . Have participate another clinical trial within 30 day ( 5 halflives compound , whichever long ) prior study drug dosing .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>